Less than 10% of individuals that would benefit from obesity jabs such as Wegovy are able to get them, caution the World Health Organization as it publishes its first recommendations on the therapies.
With in excess of 1,000,000,000 people worldwide now living with obesity, it is calling for increased and just availability to this class of drugs.
According to projections, over two billion are projected to be living with obesity by 2030 unless action is taken.
"Our new guidelines acknowledges that obesity is a long-term condition that can be managed with thorough and ongoing care," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant barriers to universal access to the injections that can aid individuals in losing significant weight, explains the organization.
Skinny Jab Supply Crisis
Even under the present most optimistic scenario, the supply of such drugs would only suffice for about 100 million people – less than 10% of those who need them, as stated by the WHO.
The advice encourages nations and manufacturers to widen access, through strategies like voluntary licensing.
The intellectual property rights on the active ingredient – the core ingredient of the drug Wegovy – is due to expire in a number of countries in 2026.
The Way Weight-Loss Injections Function
These medications imitate a biological compound to slow digestion, reduce hunger and boost feelings of fullness so users consume fewer calories.
Patients usually begin shedding pounds in the initial weeks of commencing the once-weekly jabs.
Research suggests patients may regain a significant portion after a year of halting the medication, when their normal appetite come back.
Being overweight or obese elevates your risk for developing medical conditions, like diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity concerns people in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, per the WHO.
